Summary: Many malignancies harbor mutated ras proto-oncogenes encoding 21 kDa proteins with single amino acid substitutions. Previous studies have shown that the aberrant p21 raJ proteins are potential tumor-specific antigens in that CD4'" class II major histocompatibIlity complex-restricted T cells spe· cific for the mutated segment of vanous oncogenic p21 raJ proteins can be elicited by immunization in vivo with synthetic peptides corresponding to the mutated segment. T·cell recognition of an antigenic peptide within a protein may be influenced substantially, either positively or negatively, by flanking amino acid sequences as well as by more distal immunogenic or toterogenic epitopes within the same protein. This study examined whether T cells specific for the mutated segment of an oncogenic p21 _aJ protein can be elicited by immunization in vivo with the protein. The results showed that p21 raJ protein bearing the transforming single amino ac id substitution of leucine for glutamine at residue 61 could elicit T cells specifically reactive to the mutated region of the protein in C3HJHeN mice. Thus, an abnormal p21"JJ protein specifically associated with malignant transformation can be immunogenic in vivo. These results predict that in some circumstances. mutated pllraJ proteins expressed by malignancies might elicit detectable mutation-specific T -ceH responses.
Malignant transformation is commonly associ ated with the acquisition of defined and character istic mutations of cancer-related genes (1). In many circumstances. the mutations result in the expres sion of aberrant proteins that disrupt the normal regulation of ceil growth and differentiation. The mutations are intrinsic to the process of malignant transformation and may be essential for the main· tenance of the malignant phenotype (1-3). The most thoroughly characterized cancer-related genes to become activated by somatic mutations are the ras oncogenes (4) . Mutations of ras are common in mammalian tumors (4) (5) (6) . Approximately 15-20% of all human malignancies harbor point mutations of the ras oncogenes, usually within codon 12. 13, or 61 (6.7) , and encode proteins bearing a single sub stituted amino acid at the corresponding residue (4) .
The T-cell immune system is adept at distinguish ing peptide sequences that differ by single amino acid residues (8) . Previous studies have established that synthetic peptides corresponding to the aber rant region of oncogenic p21 ra$ proteins containing single amino acid substitutions at either residue 12 or 61 can elicit class II major histocompatibility complex (MHC)-restricted peptide-specific T cells in a variety of mouse strains ex-pressing diverse class II MHC antigens (9). The results of these stud-
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ies implied that aberrant p21 ril.' proteins common to many tumors contain potentially antigenic T-cell epitopes specific for and intrinsic to the malignant phenotype.
The capaCity to generate ras peptide-specific T cells that recognize processed protein need not nec essarily mean that the parental protein is immuno genic. Inherently, antigenic peptides incorporated within larger proteins may not be recognized by T cells because of the presence of competing or inhib itory domains in other portions of the protein (10 14) . OUf study shows that mice immunized with pzr us protein-bearing leucine in place of glutamine, normally resident at position 61 ofp21,as, developed CD4 + T cells that were specifically reactive to pep· tides corresponding to the altered portion of the p2l rus [Leu51] protein. The results indicate that a T-cell epitope spanning the mutated region of an oncogenic p21,as protein can be processed and pre sented in vivo in a ~anner appropriate for eliciting specific T-cell responses.
MATERIALS AND METHODS

Reagents
Synthetic ras peptides used in the current study were synthesized and purified by Drs 
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Proliferative Assays
Proliferati ve responses of freshly harvested spleen cells were measured by suspending cells in culture medium and plating in flat-bottom 96-well plates at 2 x 10 5 cells per wen with designated an tigen at the indicated concentration in a total vol ume of 200 ",,"I per well. Plates were incubated in a hUnlldified atmosphere under 5% CO 2 tension at 37°C for 4 days. Proliferation was measured by add ing t ""Ci of eHlthymidine per well during the final 8 h of culture, then assaying incorporation of radio activity by liquid scintillation counting. Prolifera tive responses of long-term cultured T cells were similarly measured after incubating rested lympho cytes (l x 10 5 cells/well) for 4 days in 96-well plates with irradiated syngeneic spleen cells (2 x 10 5 cells! well x 3,000 rad) and antigen at the indicated con centrations.
.
RESULTS
In previous studies synthetic peptides corre sponding to the mutated segment of p21 ,as proteins bearing single amino acid substitutions at either res idue 12 or residue 61 were found to elicit Class II MHC-restricted T cells that were highly specific for the relevant substituted 'as peptide (9). It is impor tant to note that ,as peptide-induced T cells were also capable of recognizing the corresponding mu tated p21,as protein, indicating that p21,as protein can be appropriately processed and presented for recognition by primed immune T cells. The avail ability of a prokaryotic expression vector encoding an oncogenic p21 '{JS with the substitution of leucine faT glutamine allowed experiments to be conducted to examine whether an oncogenic p21 ras protein it self is immunogenic in vivo.
To the center of a putative minimal stimulatory peptide extending nine to II residues in length.
DISCUSSION
The capacity of an alien protein to elicit specific T-cell immune responses is contingent upon wheth er the protein has antigenic segments with the proper molecular configuration or amino add "mo~ tif' to bind to self MHC molecules, whether the resultant peptide/MHC molecular complex is pre sented at a concentration high enough to stimulate the antigen-specific T-cell receptor, and whether the peptide/MHC molecular complex is within the host T-cell repertoire. Our finding that p21raS[Leu61] protein elicited T cells specific for the mutated pro· tein segment indicates that an oncogenic p21 ras pro tein bearing a known antigenic segment can be ap propriately processed and presented to specifically reactive T cells in vivo. To OUf knowledge, these results are the first to show that an oncogenic p2l ras protein can be immunogenic in vivo and to suggest that oncogenic p21 ras proteins expressed by cells undergoing malignant transformation might elicit specific host T-cell immune responses. "
T cells elicited by immunization with p21 ras . [Leu 61 ] protein exhibited the CD4 + CD8 -cell surface phenot ype. In general. CD4 + T cells are poised to recognize processed soluble protein anti· gens, presented in the context of class II MHC an tigens. Functional p21 ras protein normally is bound to the inner aspect of the cell membrane (17) and, thus, may be sequestered from the afferent limb of the class II MHC-restricted T-cell immune system. However, considerable amounts of soluble p21 ras prot~in are released by tumor cells in vivo (18, 19) . Thus, abnormal p21ras proteins expressed by trans formed cells in tumor-bearing hosts should be avail able for uptake and presentation by antigen present ing cells (APe) with the potential to elicit specific autologous T-cell responses.
The extent to which the various forms of onco genic p21 ras proteins can elicit class II MHC restricted T-cell responses is not yet known. It is improbable that all oncogenic p2 tras proteins will be immunogenic in all circumstances. Variations in MHC phenotype and T-cell receptor repertoire are likely to disallow appropriate binding and/or recog nition of derivative ras peptides of particular onco genic p21 ras proteins in particular individuals. On the other hand, murine studies have suggested that the T-cell repertoire for the various forms of mu tated p21 ras may be quite extensive (9). Recently it has been noted that some cancer patients can mount specific class II MHC-restricted T-cell responses to mutated ras peptides (20, 21) . However, no evi dence h.as been published showing that the ras pep tide-specific T cells found in cancer patients re spond to protein and, in addition, correlate with the presence of malignancies expressing the corre sponding oncogenic p21 ras protein. The current data give credence to that possibility.
Autologou5 T-cell recognition of oncogenic p2 tras proteins as tumor-specific antigens might have di agnostic and/or therapeutic applications. Mutations of the rQS proto-oncogenes have been detected dur ing the early phases of malignant transformation (4). Thus, T-cell immunity to tumor-derived p21 ras pro- 
